Anavex Life Sciences Corp. (AVXL) intrinsic value & 10-year financials
Anavex Life Sciences Corp. (AVXL) has no Graham intrinsic value right now because the formula needs positive earnings.
- Graham intrinsic value
- —
- Share price (Oct 17, 2026)
- $1.31
- Market cap
- $111.7M
- Revenue (FY2025)
- —
- ROIC (10-yr avg)
- -82.4%
- Free cash flow (FY2025)
- —
AVXL 10-year financial history
| Fiscal year | Revenue | Net income | EPS (diluted) | Free cash flow | Operating margin | ROIC |
|---|---|---|---|---|---|---|
| FY2025 | — | -$46.4M | -$0.54 | — | — | -43.1% |
| FY2024 | — | -$43.0M | -$0.52 | — | — | -32.8% |
| FY2023 | — | -$47.5M | -$0.60 | — | — | -33.4% |
| FY2022 | — | -$48.0M | -$0.62 | — | — | -32.7% |
| FY2021 | — | -$37.9M | -$0.54 | — | — | -42.6% |
| FY2020 | — | -$26.3M | — | — | — | -110.6% |
| FY2019 | — | -$26.3M | — | — | — | -129.0% |
| FY2018 | — | -$17.5M | — | — | — | -78.0% |
| FY2017 | — | -$13.5M | — | — | — | -88.1% |
| FY2016 | — | -$14.7M | -$0.42 | — | — | -233.6% |
Source: annual 10-K filings on SEC EDGAR. Figures in USD.
Executive summary
ANAVEX LIFE SCIENCES CORP. revenue growth over the past decade is N/A; insufficient history prevents a reliable 10-year CAGR calculation.
ANAVEX LIFE SCIENCES CORP. has historically struggled to out-earn its cost of capital, averaging just -59.3% ROIC.
ANAVEX LIFE SCIENCES CORP. has not shown aggressive share repurchases (>10% retirement) or a major balance-sheet leverage increase (>50% net debt growth) over the 10-year window.
Benjamin Graham lens
ANAVEX LIFE SCIENCES CORP. is evaluated under Benjamin Graham's defensive framework using SEC EDGAR fundamentals using an 8.5 + 2g earnings multiple and a 5.1% AAA bond-yield baseline.